Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

133
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
133
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
70
Drug Therapy01:28

Drug Therapy

37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
37
Flail Chest-II01:26

Flail Chest-II

160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
160
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

186
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
186
Techniques of Therapeutic Communication II: Focusing, Paraphrasing, and Summarizing01:23

Techniques of Therapeutic Communication II: Focusing, Paraphrasing, and Summarizing

7.7K
Focusing involves centering a conversation on a message's critical elements or concepts. Focusing is valuable if the talk is vague or patients begin to repeat themselves. Sometimes, when patients are asked about their symptoms, they may go off-topic and try to tell their entire life story. Respectfully, the nurse should bring the conversation back into focus.
This therapeutic technique can also be used when a patient brings up pertinent information during a health-related conversation. The...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.

Human pathology·2026
Same author

One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Progressive HNF1A-MODY pathophysiology revealed by a translational mouse model.

JCI insight·2026
Same author

Bone phenotype in familial partial lipodystrophy type 2: Insulin resistance and sclerostin.

Diabetes & metabolism·2026
Same author

Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.

European thyroid journal·2026
Same journal

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.4K

Chapter 11: Treatment modalities.

Grégory Baud1, Stéphanie Espiard2, Camille Buffet3

  • 1Department of General and Endocrine Surgery, CHU de Lille, 59000 Lille, France.

Annales D'Endocrinologie
|January 16, 2025
PubMed
Summary
This summary is machine-generated.

Choosing the best treatment for primary hyperparathyroidism requires careful consideration of benefits and risks. This review examines surgery, local destruction, and medical management options.

Keywords:
Medical treatmentParathyroidectomyPrimary hyperparathyroidismSurgical approachesThermoablation

More Related Videos

Treatment of Facial Deformities using 3D Planning and Printing of Patient-Specific Implants
07:11

Treatment of Facial Deformities using 3D Planning and Printing of Patient-Specific Implants

Published on: May 23, 2020

7.3K
Structured Motor Rehabilitation After Selective Nerve Transfers
09:34

Structured Motor Rehabilitation After Selective Nerve Transfers

Published on: August 15, 2019

21.9K

Related Experiment Videos

Last Updated: Jun 2, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.4K
Treatment of Facial Deformities using 3D Planning and Printing of Patient-Specific Implants
07:11

Treatment of Facial Deformities using 3D Planning and Printing of Patient-Specific Implants

Published on: May 23, 2020

7.3K
Structured Motor Rehabilitation After Selective Nerve Transfers
09:34

Structured Motor Rehabilitation After Selective Nerve Transfers

Published on: August 15, 2019

21.9K

Area of Science:

  • Endocrinology
  • Surgical Oncology
  • Internal Medicine

Background:

  • Primary hyperparathyroidism management necessitates balancing treatment benefits and risks.
  • Selecting the optimal therapeutic strategy presents significant challenges.

Purpose of the Study:

  • To provide a comprehensive overview of available treatment modalities for primary hyperparathyroidism.
  • To analyze the distinct approaches including surgical, local destruction, and medical management.

Main Methods:

  • Review of established and emerging treatment options for primary hyperparathyroidism.
  • Comparative analysis of benefits and risks associated with each modality.

Main Results:

  • Surgery offers definitive treatment but carries surgical risks.
  • Local destruction provides a minimally invasive option with varying efficacy.
  • Medical management aims to control hypercalcemia and its complications.

Conclusions:

  • The choice of treatment for primary hyperparathyroidism should be individualized based on patient-specific factors.
  • A thorough understanding of each modality's profile is crucial for informed decision-making.